Since May 2022, monkeypox outbreaks have occurred in several countries around the world. According to the CDC, as of August 26th 2022, there have been more than 47,000 cases of monkeypox worldwide, involving 99 countries, including the United States, the United Kingdom, and others (Figure 1).
Figure 1: CDC Data of Monkeypox Outbreak Globally
Monkeypox, also known as monkey smallpox, has been designated as a zoonotic disease that originated in the tropical rainforest region of West and Central Africa. The pathogen of monkeypox is monkeypox virus (MPXV), which was first identified in 1958 in experimental crab-eating monkeys (Figure 2).
Monkeypox virus is transmitted primarily through animals, with people becoming infected after being bitten or in close contact with an animal carrying the virus, and through blood, body fluids and contaminants. Patients with monkeypox are contagious at the onset of symptoms.
The most important symptom of monkeypox virus infection is the skin rash. The rash can vary in number from a few to several thousand and tends to be concentrated on the face, palms and soles of the feet, and can also be found in the mouth and eyes.
Figure 2: Monkeypox Observed under the Microscope
Through the self-built SingleB® Fast mAb discovery platform, DetaiBio can obtain nearly 100 MPXV antibodies in 49 days, involving 4 key epitopes, A35R, B6R, A29L and M1R, which significantly improves the efficiency of monoclonal antibody discovery, saving time for antibody development. Detaibio preferentially selected eukaryotic expression of monkeypox antigens to immunize mice and directly screened monkeypox antigen-specific memory B cells and plasma cells from peripheral blood, obtaining antibodies with natural maturation and rich sequence diversity in vivo.
Based on the customer’s requirements, DetaiBio can develop a sandwich antibody pair suitable for their specific application requirements, making it applicable to ELISA kit development, colloidal gold test strip development and other researches IVD field.
Results of FACS screening of MBC and DeepLight® screening of PBC
Detai Bioengineering Co., Ltd. (“DetaiBio”), established in 2013, is a CRO vendor focusing on antibody discovery and functional protein research file. DetaiBio is aiming to provide high quality and economic offer service to speed up life science for our client in different fields, such as antibody drug discovery, in-vitro diagnosis and academic research.
The main services offer by DetaiBio:
——SingleB® for antibody/VHH discovery service
——High-throughput recombinant antibody expression service (2 week delivery)
——Hybridoma sequencing service
——Customized protein expression service ( E.coli, Mammalian)